ClinicaliQ Trial Snapshot
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting • Phase III • Oncology • NCT07225946.
- Treatment being tested: Pasritamig (a novel therapeutic agent) combined with docetaxel chemotherapy versus docetaxel alone in metastatic castration-resistant prostate cancer (mCRPC), with primary endpoint of radiographic progression-free survival (rPFS).
- Patient eligibility overview: Men with metastatic castration-resistant prostate cancer who have progressed despite androgen deprivation therapy; specific inclusion/exclusion criteria regarding prior treatments, performance status, and organ function apply (full details available in protocol).
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Eligibility Snapshot
- : * Have histologically confirmed adenocarcinoma of the prostate * Have disease that is metastatic at the time of the screening as determined by the investigator * Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.